Biogen Inc. Common Stock (BIIB) Valuation
Historical valuation analysis based on 500 data points (2024-08-30 to 2026-08-28)
Biogen is an established biopharmaceutical company focused on treatments for neurodegenerative and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and con...
Biogen Inc. Common Stock (BIIB) currently trades at a P/E ratio of 23.76 (historical range: 11.24–25.81, median: 15.03), placing it at the 96th percentile — expensive relative to its history, P/S ratio of 3.28 (range: 1.69–3.31, 100th percentile — expensive relative to its history), EV/EBITDA of 100.58 (range: 3.80–101.32, 100th percentile).
Over the historical period (2024-08-30 to 2026-08-28), Biogen Inc. Common Stock's P/E ratio has expanded by 26% over the observed period (from an average of 14.3 to 18.0).
Biogen Inc. Common Stock appears overvalued relative to its own historical valuation range, trading at elevated multiples across most metrics.
Historical Valuation Metrics
| Metric | Current | Min | Median | Max | Percentile | Assessment |
|---|---|---|---|---|---|---|
| P/E Ratio | 23.76 | 11.24 | 15.03 | 25.81 | 96th | expensive relative to its history |
| P/S Ratio | 3.28 | 1.69 | 2.44 | 3.31 | 100th | expensive relative to its history |
| EV/EBITDA | 100.58 | 3.80 | 20.72 | 101.32 | 100th | expensive relative to its history |
| FCF Yield | 0.02 | 0.01 | 0.04 | 0.14 | 19th | expensive relative to its history |